Showing results (351-360 of 1,831) with videos related to

Sort By:
Pageof 184
ESMO Open|June 21, 2025
Do BRAF-targeted therapies have a role in the era of immunotherapy?J Braden, J W Conway, J S Wilmott, et al.
ESMO Open|March 19, 2025
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patientsS Gupta, M A Climent Duran, S S Sridhar, et al.
ESMO Open|March 19, 2025
Comparative profiling of surgically resected primary tumors and their lymph node metastases in small-cell lung cancerK Csende, B Ferencz, K Boettiger, et al.
ESMO Open|March 19, 2025
Immune-related adverse events are associated with better event-free survival in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage triple-negative breast cancerA Rios-Hoyo, J Dai, T Noel, et al.
ESMO Open|May 1, 2025
Precision oncology in biliary tract cancer: the emerging role of liquid biopsyM de Scordilli, M Bortolot, S Torresan, et al.
ESMO Open|May 1, 2025
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)R Galot, C Le Tourneau, L Licitra, et al.
ESMO Open|May 2, 2025
Multicenter analysis of high-dose chemotherapy regimens for the treatment of patients with refractory or recurrent germ cell tumorsA Chehrazi-Raffle, M Zugman, H Ebrahimi, et al.
ESMO Open|April 30, 2025
Real-world comparison of pembrolizumab alone and combined with chemotherapy in metastatic lung adenocarcinoma patients with PD-L1 expression ≥50H H Hektoen, K M Tsuruda, O T Brustugun, et al.
ESMO Open|April 30, 2025
Refining prognostic tools for luminal breast cancer: genetic insights and comprehensive analysisL A Sinberger, T Zahavi, N Keren-Khadmy, et al.
ESMO Open|April 16, 2025
Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trialM Saint-Ghislain, S Chabaud, F Dalenc, et al.
Pageof 184